MAIA Biotechnology, Inc. (MAIA) company profile
Close on Nov 17, 2026Market cap $76.03MP/E –Yield –
About MAIA Biotechnology
Pharmaceutical Preparations, SIC 2834
MAIA Biotechnology, Inc. is a clinical-stage biotechnology entity engaged in the research, development, and advancement of targeted oncology treatments. The enterprise primarily focuses on investigational therapies targeting telomeres and cancer cell processes to combat complex malignancies. Its therapeutic pipeline includes clinical and technological development centered on THIO (ateganosine), aimed at addressing severe oncological conditions for patients with advanced cancers. The enterprise coordinates research activities alongside collaboration and licensing agreements established with research institutions and industry partners.
The organization conducts administrative, research, and regulatory activities with domestic jurisdictions in the United States as well as foreign authorities, such as the Australian Taxation Office. MAIA Biotechnology, Inc. maintains its principal executive offices in Chicago, Illinois.
Summary of the business section of MAIA Biotechnology's latest annual report, written by StockData.
Company profile
Company
- Legal name
- MAIA Biotechnology, Inc.
- Founded
- 2018
- Headquarters
- Chicago, IL
- Address
- 444 West Lake Street, Suite 1700 60606
- Phone
- (312) 416-8592
- Website
- maiabiotech.com
- Employees
- 13, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- GRANT THORNTON LLP, Charlotte, North Carolina
Stock & identifiers
- Ticker
- MAIA
- Exchange
- NYSE
- IPO date
- Jul 29, 2022
- Shares outstanding
- 61M, Aug 10, 2026
- Public float
- $48.95M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 1878313
- CUSIP
- 552641102
- ISIN
- US5526411021
- FIGI
- BBG0113Q7J88
- Share class FIGI
- BBG0113Q7J97
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Vlad Vitoc | Chief Executive Officer, Director | 1,359,221 |
| Sergei Gryaznov | Chief Scientific Officer | 46,511 |
| Jeffrey C. Himmelreich | Head of Finance | – |
| Stan Smith | Director | 1,619,178 |
| Ramiro Guerrero | Director | 773,296 |
| Cristian Luput | Director | 437,628 |
| Jean-Manasse Theagene | Director | – |
| Ngar Yee Louie | Director | 1,248,888 |
| Steven M. Chaouki | Director | 151,873 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Option awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Vlad Vitoc Chief Executive Officer and President | $612.33K | $334.81K | $1.12M | $13.01K | $2.08M | +53% |
| Jeffrey C. Himmelreich Head of Finance | $272.92K | $68.23K | $69.60K | $10.24K | $420.99K | +24% |
| Sergei Gryaznov Chief Scientific Officer | $478.50K | $213.81K | $562.24K | $12.74K | $1.27M | +36% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jul 29, 2022
- Offer price
- $5.00
- Securities offered
- 2,000,000
- Gross proceeds
- $10.00M
- Exchange
- NYSE American
- First trading day
- Jul 28, 2022
- First-day close
- $4.46-10.8%
- Lock-up ends (est.)
- Jan 24, 2023
“We are offering 2,000,000 shares of our common stock at an initial public offering price of $5.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“of December 31, 2025, we had a total of 13 full-time employees which includes one employee employed by our Romanian subsidiary.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Nov 15, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Nov 22, 2022 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Jul 29, 2022 | IPO | Initial public offering priced (424B4 prospectus) |
| Jul 27, 2022 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?